The effect of intravenous ferric carboxymaltose on cardiac reverse remodelling following cardiac resynchronization therapy—the IRON-CRT trial

RCT in 75 patients with heart failure, iron deficiency and LVEF <45% at least 6  months after cardiac resynchronisation therapy found ferric carboxymaltose improved LVEF more than standard of care (+4.22% vs -0.23%, p<0.001) at 3 months.

Source:

European Heart Journal